Despite these limitations, the findings reported here support that treatment with the ABCA1 agonist CS-6253 in cynomolgus monkeys can lead to favorable AD biomarkers changes that, if confirmed in ensuing human studies, will allow the generation of useful biomarkers to guide CS-6253 drug development into the AD space. The gene discussed is ABCA1; the disease is Alzheimer disease.